Details for Patent: 10,227,342
✉ Email this page to a colleague
Which drugs does patent 10,227,342 protect, and when does it expire?
Patent 10,227,342 protects EXKIVITY and is included in one NDA.
This patent has sixty-two patent family members in thirty-nine countries.
Summary for Patent: 10,227,342
Title: | Heteroaryl compounds for kinase inhibition |
Abstract: | Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein. |
Inventor(s): | Huang; Wei-Sheng (Acton, MA), Gong; Yongjin (Belmont, MA), Li; Feng (Winchester, MA), Bencivenga; Nicholas E. (Malden, MA), Dalgarno; David C. (Brookline, MA), Kohlmann; Anna (Winchester, MA), Shakespeare; William C. (Southborough, MA), Thomas; Ranny M. (Sharon, MA), Zhu; Xiaotian (Newton, MA), West; Angela (Franklin, MA), Youngsaye; Willmen (Boston, MA), Zhang; Yun (Acton, MA), Zhou; Tianjun (Belmont, MA) |
Assignee: | ARIAD PHARMACEUTICALS, INC. (Cambridge, MA) |
Application Number: | 15/319,637 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,227,342
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | EXKIVITY | mobocertinib succinate | CAPSULE;ORAL | 215310-001 | Sep 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,227,342
PCT Information | |||
PCT Filed | May 13, 2015 | PCT Application Number: | PCT/US2015/030576 |
PCT Publication Date: | December 23, 2015 | PCT Publication Number: | WO2015/195228 |
International Family Members for US Patent 10,227,342
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2015277786 | ⤷ Try a Trial | |||
Australia | 2019206024 | ⤷ Try a Trial | |||
Brazil | 112016029662 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |